Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00876148
Recruitment Status : Completed
First Posted : April 6, 2009
Last Update Posted : April 6, 2009
Sponsor:
Information provided by:
Azienda Ospedaliera San Giovanni Battista

Brief Summary:
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.

Condition or disease
Hepatitis B Virus Allograft Hematological Malignancies

Layout table for study information
Study Type : Observational
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
A cohort of patients undergoing allografting for hematological malignancies
Criteria

Inclusion Criteria:

  • All patients undergoing an allograft for hematological malignancies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00876148


Locations
Layout table for location information
Italy
Azienda ospedaliera S Giovanni Battista
Torino, Italy
Sponsors and Collaborators
Azienda Ospedaliera San Giovanni Battista
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00876148    
Other Study ID Numbers: LAM Allo SCT
First Posted: April 6, 2009    Key Record Dates
Last Update Posted: April 6, 2009
Last Verified: April 2009
Keywords provided by Azienda Ospedaliera San Giovanni Battista:
Incidence of hepatitis B after allografting
Risk of hepatitis B reactivation
Lamivudine prophylaxis
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hematologic Neoplasms
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Neoplasms
Hepadnaviridae Infections
DNA Virus Infections
Neoplasms by Site
Hematologic Diseases